SRR934930
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.546
- TGF_BETA_SIGNALING+0.543
- UNFOLDED_PROTEIN_RESPONSE+0.506
- E2F_TARGETS+0.493
- G2M_CHECKPOINT+0.477
- PROTEIN_SECRETION+0.449
- MYC_TARGETS_V2+0.427
- MTORC1_SIGNALING+0.388
- DNA_REPAIR+0.369
- MITOTIC_SPINDLE+0.336
Top 10 suppressed
- KRAS_SIGNALING_DN-0.473
- PANCREAS_BETA_CELLS-0.358
- APICAL_SURFACE-0.294
- MYOGENESIS-0.273
- SPERMATOGENESIS-0.252
- BILE_ACID_METABOLISM-0.200
- HEDGEHOG_SIGNALING-0.183
- ESTROGEN_RESPONSE_EARLY-0.181
- ESTROGEN_RESPONSE_LATE-0.158
- APICAL_JUNCTION-0.134
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934817 | — | — | 0.935 |
| 2 | SRR934851 | — | — | 0.915 |
| 3 | SRR934939 | — | — | 0.905 |
| 4 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.899 |
| 5 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.896 |
| 6 | SRR934935 | — | — | 0.894 |
| 7 | BDC31CC4-927C-49B1-819B-5119AA8422E8 | — | — | 0.892 |
| 8 | 31A652B1-3BEB-4D78-BCA0-4C153EBC41E8 | — | — | 0.892 |
| 9 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.889 |
| 10 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.546 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.543 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.506 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.493 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.477 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.449 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.427 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.388 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.369 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.336 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.329 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.327 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.283 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.283 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.272 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.226 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.212 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.176 | Inavolisib | — uncovered |